Drug intelligence / Profile preview

FT-04

Development stage: Preclinical
Lead developer: Fekra Therapeutics
Modality: Small Molecules

Overview

FT-04 is a pharmaceutical candidate currently in the discovery phase of development by Fekra Therapeutics, targeting unspecified inflammatory diseases. Fekra Therapeutics is a biotechnology company that leverages a proprietary platform to develop small molecule inhibitors, particularly focusing on covalent and non-covalent inhibitors of kinases and other signaling proteins. As an early-stage program, the specific molecular target and mechanism of action for FT-04 have not yet been publicly disclosed, but it represents the company's strategic expansion into the inflammatory and immunological therapeutic space.

Beyond the preview

Go deeper on FT-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FT-04.

Explore the full profile